Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
FONDAPARINUX SODIUM vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Heparin binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin (factor IIa) and other serine proteases (factors Xa, IXa, XIa, XIIa) in the coagulation cascade, thereby preventing fibrin clot formation.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; subsequent dose adjusted based on aPTT. Typical infusion rate: 20,000–40,000 units/24 hours.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
Terminal elimination half-life is 1-2 hours at therapeutic doses, dose-dependent: 30-60 min after IV bolus of 25 U/kg, increasing to 1.5-2.5 hours after 400 U/kg. Prolonged in hepatic/renal impairment and pulmonary embolism. Clinical context: continuous infusion achieves steady-state after ~4-6 hours.
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Heparin is eliminated primarily via hepatic metabolism and renal excretion. Approximately 50% of a dose undergoes hepatic desulfation and depolymerization to form uroheparin, which is excreted in urine. Unchanged heparin is cleared renally via saturable, dose-dependent mechanisms. Biliary/fecal elimination is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant